Prostate cancer

In August 2026, the Spanish Network of HTA Agencies published the annual List of New and Emerging Technologies for 2025. The evaluations of a total of 66 technologies, covering multiple areas such as cardiovascular, diagnostic imaging, e-Health, endoscopy, gastrointestinal, in-vitro diagnostics, interventional radiology, men’s health, urology, neurology and neurosurgery, neuromodulation, neurovascular, obstetrics and gynecology, ophthalmology, orthopedics, pulmonary, radiotherapy, spine, and surgical procedures, have been assigned for evaluation to the relevant HTA bodies.

The Danish Health Data Authority quarterly updates the Health Care Classification System (SKS). The latest version was published in mid-June 2026 to come into force on July 1, 2026. Among other changes, 54 new procedure codes concerning cardiovascular, diagnostic imaging, gastrointestinal, interventional radiology, men’s health, urology, obstetrics and gynecology, surgical procedures, dermatology, and some other fields were introduced.

On January 30, 2026, the Federal Ministry of Labor, Social Affairs, Health, Care and Consumer Protection (BMASGPK) and Gesundheit Österreich GmbH (GÖG) jointly presented the National Cancer Framework Program 2026-2035. It serves as a strategic compass, setting the direction for cancer control and care in Austria over the next ten years, although it is not legally binding. The Program comprises four areas of action, 22 objectives, and 113 measures.

On January 14, 2026, the French Ministry of Health, Family, Autonomy and People with Disability published the Order setting DRG tariffs and tariffs for other packages and supplements for 2026. The released tariffs are in effect from January 1, 2026, and include new, higher DRG tariffs for several procedures, such as HIFU destruction of prostate lesions, as well as updates to packages for organ perfusion technologies for transplantation.

In December 2025, the Danish Healthcare Quality Institute (DHQI) released a methodological document clarifying the processes of health economic analyses associated with the clinical guidelines and the DHQI Council’s decision-making. Furthermore, the first two health economic analyses associated with the clinical guidelines were published concerning prostate-specific membrane antigen (PSMA)-PET/CT in prostate cancer and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.

On October 16, 2025, the Federal Joint Committee (G-BA) launched the consultation procedure on a risk-adapted prostate-specific antigen (PSA) and MRI-based screening for the early detection of prostate cancer, in line with §135 SGB V (G-BA Directive on Ambulatory Care Methods; conceptually new diagnostic and therapeutic methods). Public comments may be submitted electronically by November 23, 2025.

The Danish Health Data Authority quarterly updates the Health Care Classification System (SKS). The latest version was published in mid-September 2025 to come into force on October 1, 2025. Among other changes, four new procedure codes were introduced concerning men's health, radiotherapy, and surgical procedures.

On July 10, 2025, a decision of the National Union of Health Insurance Funds regarding the update of the CCAM Classification of Medical Procedures was published. The update includes the provisional registration of one procedure code for transrectal HIFU destruction of prostate lesions and changes to indications and billing notes for several existing codes. The update takes effect on September 1, 2025.

The French National Authority for Health (HAS) released new recommendations regarding the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following the May 2025 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). One favourable opinion was issued concerning add-on reimbursement for medical device in the men’s health field.

In March 2025, the Decision Forum for the "New Methods" framework made a favorable coverage decision for robotic-assisted prostatectomy, hysterectomy, and rectal resection in cancer indications.

Between late February 2024 and early March 2025, seven more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, 59 health apps are currently available in the DiGA Directory, and ten health apps were delisted from the Directory.

In February 2025, the MTP Council announced national evaluations of two technologies within the Orderly introduction framework in Sweden. The Council commissioned the Dental and Pharmaceutical Benefits Agency (TLV) to perform a health economic evaluation of rectal spacers (SpaceOAR Hydrogel and Barrigel) used during radiotherapy in prostate cancer (re-evaluation) and AI-based solution (Stratipath Breast) for breast cancer risk assessment.